These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 16093780)

  • 41. Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.
    Picod A; Provôt F; Coppo P
    Presse Med; 2019 Nov; 48(11 Pt 2):319-327. PubMed ID: 31759790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy.
    Robson WL; Tsai HM
    Pediatrics; 2002 Feb; 109(2):322-5. PubMed ID: 11826215
    [No Abstract]   [Full Text] [Related]  

  • 43. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
    Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
    Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.
    Tun NM; Villani GM
    J Thromb Thrombolysis; 2012 Oct; 34(3):347-59. PubMed ID: 22547089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura.
    Sahud MA; Claster S; Liu L; Ero M; Harris K; Furlan M
    Br J Haematol; 2002 Mar; 116(4):909-11. PubMed ID: 11886400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Thrombotic thrombocytopenic purpura. Reduced activity of von Willebrand factor cleaving protease].
    Kunze A; Terborg C; Gerth J; Heide G; Witte OW
    Nervenarzt; 2004 Aug; 75(8):785-9. PubMed ID: 15034657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).
    Gerritsen HE; Turecek PL; Schwarz HP; Lämmle B; Furlan M
    Thromb Haemost; 1999 Nov; 82(5):1386-9. PubMed ID: 10595623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab.
    Caramazza D; Quintini G; Abbene I; Malato A; Saccullo G; Lo Coco L; Di Trapani R; Palazzolo R; Barone R; Mazzola G; Rizzo S; Ragonese P; Aridon P; Abbadessa V; Siragusa S
    Transfusion; 2010 Dec; 50(12):2753-60. PubMed ID: 20576013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.
    George JN
    Am J Hematol; 2012 May; 87 Suppl 1():S88-91. PubMed ID: 22407740
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel therapeutic approaches for thrombotic thrombocytopenic purpura.
    Tanhehco YC; Arepally G; Metjian A
    Curr Opin Hematol; 2017 Nov; 24(6):521-528. PubMed ID: 28759473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura.
    Loof AH; van Vliet HH; Kappers-Klunne MC
    Br J Haematol; 2001 Mar; 112(4):1087-8. PubMed ID: 11324640
    [No Abstract]   [Full Text] [Related]  

  • 55. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
    Moake JL
    Semin Hematol; 2004 Jan; 41(1):4-14. PubMed ID: 14727254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma.
    Kentouche K; Budde U; Furlan M; Scharfe V; Schneppenheim R; Zintl F
    Acta Paediatr; 2002; 91(10):1056-9. PubMed ID: 12434890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current management of thrombotic thrombocytopenic purpura.
    Kremer Hovinga JA; Meyer SC
    Curr Opin Hematol; 2008 Sep; 15(5):445-50. PubMed ID: 18695366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura.
    Snider CE; Moore JC; Warkentin TE; Finch CN; Hayward CP; Kelton JG
    Am J Hematol; 2004 Dec; 77(4):387-90. PubMed ID: 15551280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
    Poullin P
    Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura.
    Studt JD; Kremer Hovinga JA; Furlan M; Lämmle B
    Blood; 2003 Aug; 102(3):1148. PubMed ID: 12869494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.